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individuals with response to 4-week n-3 fatty acid
supplementation from krill oil versus fish oil
Vanu R Ramprasath1,2, Inbal Eyal3, Sigalit Zchut3 and Peter JH Jones1,2*Abstract
Background: Due to structural differences, bioavailability of krill oil, a phospholipid based oil, could be higher than
fish oil, a triglyceride-based oil, conferring properties that render it more effective than fish oil in increasing omega-3
index and thereby, reducing cardiovascular disease (CVD) risk.
Objective: The objective was to assess the effects of krill oil compared with fish oil or a placebo control on plasma and
red blood cell (RBC) fatty acid profile in healthy volunteers.
Participants and methods: Twenty four healthy volunteers were recruited for a double blinded, randomized, placebo-
controlled, crossover trial. The study consisted of three treatment phases including krill or fish oil each providing
600 mg of n-3 polyunsaturated fatty acids (PUFA) or placebo control, corn oil in capsule form. Each treatment lasted 4
wk and was separated by 8 wk washout phases.
Results: Krill oil consumption increased plasma (p = 0.0043) and RBC (p = 0.0011) n-3 PUFA concentrations, including
EPA and DHA, and reduced n-6:n-3 PUFA ratios (plasma: p = 0.0043, RBC: p = 0.0143) compared with fish oil consumption.
Sum of EPA and DHA concentrations in RBC, the omega-3 index, was increased following krill oil supplementation
compared with fish oil (p = 0.0143) and control (p < 0.0001). Serum triglycerides and HDL cholesterol concentrations
did not change with any of the treatments. However, total and LDL cholesterol concentrations were increased following
krill (TC: p = 0.0067, LDL: p = 0.0143) and fish oil supplementation (TC: p = 0.0028, LDL: p = 0.0143) compared with control.
Conclusions: Consumption of krill oil was well tolerated with no adverse events. Results indicate that krill oil could be
more effective than fish oil in increasing n-3 PUFA, reducing n-6:n-3 PUFA ratio, and improving the omega-3 index.
Trial registration: ClinicalTrials.gov, NCT01323036
Keywords: Krill oil, Fish oil, Omega-3 index, Fatty acids, HumanBackground
Epidemiological and clinical studies have shown various
health benefits with consumption of fish and sea foods
[1-6]. These positive health outcomes are attributed to
the presence of n-3 polyunsaturated fatty acids (PUFA)
in foods, including eicosapentaenoic acid (EPA) and doc-
osahexaenoic acid (DHA). Krill oil, extracted from
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article, unless otherwise stated.a rich source of n-3 PUFA including EPA and DHA. Krill
oil was found to be Generally Recognized as Safe (GRAS)
by the American Food and Drug Administration (FDA)
and obtained a Novel Food status from the European
Union. Krill oil is comprised of n-3 PUFA, antioxidant
carotenoid astaxanthin, vitamins A and E, phospholipids
(PL) as well as various other fatty acids [7,8]. Furthermore,
numerous clinical and pre-clinical trials have shown that
krill oil is safe and well tolerated, with no indication of
adverse effects [9-13]. Consumption of krill oil increases
plasma EPA and DHA levels in normal, overweight and
obese participants [10].
Pre-clinical studies have shown that absorption of fatty
acids attached to PL into target organs such as heart,ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Baseline characteristics of participants (n = 24)
Parameter Mean STD
Age (Y) 28.23 5.35
Body weight (Kg) 68.27 11.92
Height (m) 1.69 0.07
BMI (kg/m2) 23.76 2.96
Waist (cm) 78.28 8.25
Hip (cm) 92.07 5.18
Waist/Hip ratio 0.85 0.08
Systolic BP (mmHg) 108.07 10.21
Diastolic BP (mmHg) 72.01 7.69
Heart rate 69.17 9.28
TG (mg/dL) 91.23 36.58
HDL (mg/dL) 53.16 13.45
LDL (mg/dL) 103.51 22.77
Total cholesterol (mg/dL) 175.61 23.39
WBC count (X109/L) 5.93 1.20
RBC (X1012/L) 4.70 0.51
Hematocrit (L/L) 0.41 0.04
Hemoglobin (g/L) 141.33 15.38
Platelet count (X109/L) 219.88 34.53
Neutrophils (%) 53.09 7.81
Lymphocytes (%) 36.25 7.81
Monocytes (%) 8.14 2.16
Eosinophils (%) 2.16 1.13
Basophils (%) 0.48 0.17
MCV (fl.) 88.10 6.74
MCH (pg) 30.21 2.69
MCHC (g/L) 342.46 6.09
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attached to glycerol as triglycerides (TG) [14]. Krill and
fish oils differ in their composition where krill oil is
comprised of PL and TG and fish oil is comprised of
only TG. The primary PL in krill oil is phosphatidylcho-
line (PC), with 40% of the total fatty acids attached to
the PC being EPA and DHA [15].
Results from animal and human studies suggest that
krill oil is more effective compared with fish oil in im-
proving CVD risk markers [11,16]. Metabolic effects of
krill oil were reported to be similar to those of fish oil
but at lower doses of EPA and DHA in healthy volun-
teers [17]. However, although superior bioavailability of
n-3 PUFA in krill oil over fish oil was suggested, none of
the studies managed to show improvement in absorption
of n-3 fatty acids with krill oil over fish oil. At the most,
data from a bioavailability study in humans showed a
tendency for higher bioavailability for EPA after krill oil
consumption compared with fish oil [18], however, this
study tested an acute single dose of n-3 PUFA over 48 h.
To the best of our knowledge, no published literature
has compared the effects of krill and fish oils after longer
term consumption with a larger sample size using a ran-
domized crossover design. Additionally, no randomized
controlled trials have been conducted to compare the in-
corporation of n-3 PUFA to RBC membranes after con-
sumption of krill and fish oil.
The objective of the present trial was therefore to as-
sess the effects of krill oil compared with fish oil and a
placebo control (corn oil) on plasma and RBC fatty acid
profile in healthy volunteers following 4 wk of supple-
mentation. Specific objectives included assessment and
comparison of serum lipid profile in healthy volunteers
at baseline and following 4 wk of intervention with krill
versus fish oils.
Results
Thirty four participants (20 males and 14 females) were
screened out of which 24 (12 males and 12 females)
were eligible and enrolled into the study. All participants
completed the study and as such there were no drop
outs. Table 1 shows baseline characteristics of the partic-
ipants involved. Participants were healthy and of age,
28.2 ± 5.4 y with body weight and BMI of 68.3 ± 11.9
(kg) and 23.8 ± 3 (body weight in kg/height in M2) re-
spectively. Vital signs including body weight, systolic
and diastolic blood pressure and heart rate were within
normal ranges. No significant changes were observed for
body weight, BMI, waist circumference, systolic and dia-
stolic blood pressure or heart rates after treatment with
krill or fish oil compared with control phase (Data not
shown).
Initial statistical tests that were carried out aimed to
test the efficiency of the washout period. No significantdifferences were seen between baselines of different
phases for all parameters measured in plasma and RBC
which indicate that the washout period was sufficient to
wash out or revert back the levels of n-3 fatty acids in
both the plasma and the RBC back to baseline levels.
Table 2 shows the plasma fatty acid profiles of the par-
ticipants during the study. Increased plasma EPA and
DHA levels (p < 0.0001 and p < 0.0002, respectively) were
observed with both krill and fish oil treatments com-
pared with control. Krill oil consumption elevated (p =
0.0043) plasma EPA levels compared with fish oil.
Plasma concentrations of DPA were found to be elevated
after treatment with both krill oil (p = 0.011) and fish oil
(p = 0.014) compared with control. Levels of total n-3
fatty acids were also increased (p < 0.0001) after supple-
mentation of krill oil and fish oil compared with control.
In addition, krill oil consumption increased the level of
total n-3 PUFA compared with fish oil (p = 0.0043). Simi-
lar results were obtained for the sum of EPA and DHA
Table 2 Plasma composition of fatty acids and their changes with different interventions
Parameter Treatment Baseline End-Point Change
Mean ± STD P. value1 Mean ± STD P. value1 Mean ± STD P. value1
EPA Krill oil 0.80 ± 0.31 0.5134 1.97 ± 0.58*# <0.0001 1.17 ± 0.52*# <0.0001
Fish oil 0.82 ± 0.36 1.54 ± 0.69* 0.71 ± 0.46*
Corn oil 0.86 ± 0.36 0.79 ± 0.43 −0.06 ± 0.36
DPA Krill oil 0.61 ± 0.31 0.9087 0.79 ± 0.27* 0.0048 0.15 ± 0.23* 0.0076
Fish oil 0.64 ± 0.24 0.68 ± 0.28 0.04 ± 0.18*
Corn oil 0.64 ± 0.25 0.61 ± 0.16 −0.03 ± 0.19
DHA Krill oil 2.90 ± 0.58 0.5134 3.86 ± 0.89* <0.0001 0.96 ± 0.69* <0.0001
Fish oil 2.88 ± 0.59 3.72 ± 0.66* 0.84 ± 0.55*
Corn oil 3.03 ± 0.66 2.80 ± 0.60 −0.24 ± 0.69
Total n-3 PUFA Krill oil 4.97 ± 0.69 0.8465 7.20 ± 1.35*# <0.0001 2.23 ± 1.13*# <0.0001
Fish oil 4.96 ± 0.59 6.51 ± 0.97* 1.55 ± 0.83*
Corn oil 5.13 ± 0.95 4.79 ± 0.63 −0.34 ± 0.86
EPA + DHA Krill oil 3.70 ± 0.63 0.7470 5.83 ± 1.31*# <0.0001 2.13 ± 1.02*# <0.0001
Fish oil 3.70 ± 0.65 5.26 ± 0.95* 1.55 ± 0.73*
Corn oil 3.89 ± 0.85 3.59 ± 0.59 −0.30 ± 0.76
n-6:n-3 ratio Krill oil 7.06 ± 1.18 0.5818 4.88 ± 1.37*# <0.0001 −2.17 ± 1.05*# <0.0001
Fish oil 7.21 ± 0.93 5.32 ± 0.99* −1.89 ± 0.91*
Corn oil 7.12 ± 1.4 7.57 ± 1.06 0.44 ± 0.95
Total SFA Krill oil 43.46 ± 1.85 0.3247 43.03 ± 1.63 0.0226 −0.43 ± 1.93 0.0787
Fish oil 42.92 ± 1.32 43.65 ± 1.06* 0.73 ± 1.44
Corn oil 42.13 ± 4.74 42.53 ± 2.13 0.40 ± 5.04
Total MUFA Krill oil 17.23 ± 2.93 0.8825 16.29 ± 2.42* 0.0226 −0.94 ± 2.86 0.8465
Fish oil 16.84 ± 2.47 16.06 ± 1.74* −0.78 ± 2.51
Corn oil 17.25 ± 3.06 16.97 ± 2.21 −0.29 ± 3.11
Total PUFA Krill oil 39.31 ± 2.39 0.2748 40.68 ± 2.06 0.8825 1.36 ± 2.58 0.9592
Fish oil 40.24 ± 1.98 40.28 ± 1.73 0.05 ± 2.16
Corn oil 40.62 ± 3.92 40.51 ± 2.22 −0.11 ± 4.69
Total n-6 PUFA Krill oil 34.35 ± 2.41 0.6873 33.48 ± 2.26* 0.0007 −0.87 ± 2.08 0.0226
Fish oil 35.28 ± 1.87 33.77 ± 1.75* −1.51 ± 2.07*
Corn oil 35.49 ± 3.62 35.72 ± 2.14 0.22 ± 4.09
Values are expressed as percentage of total fatty acids except the n-6:n-3 ratio (n = 24). 1Friedman Test was used to test if there is a significant difference between treatment
groups regarding the results in baseline, end-point and change. * and # indicate significant difference compared with corn and fish oil treatments respectively.
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DHA in plasma (p < 0.0001) compared with control.
Furthermore, krill oil increased the plasma concentrations
of EPA +DHA compared with fish oil (p = 0.0011).
No significant changes in total saturated fatty acids
(SFA), PUFA and mono-unsaturated fatty acids (MUFA)
concentrations were observed between the three treat-
ments except for an increase in SFA and a decrease in
MUFA with fish oil intake (p = 0.0143) compared with
control (Additional file 1: Table S1). A decrease in
MUFA was also observed after krill oil intake (p = 0.041)
compared with control. Total n-6 PUFA concentrations
were reduced after both krill (p = 0.0043) and fish (p =0.0011) oil treatments, compared with control. However,
no significant differences were observed in the n-6
PUFA concentrations between krill and fish oil treat-
ments. Both krill and fish oil treatments reduced (p <
0.0001) the ratio between n-6 and n-3 fatty acids com-
pared with control. The ratio of n-6:n-3 fatty acids was
found to be reduced (p = 0.0043) by krill oil treatment
compared with fish oil treatment.
Table 3 shows the RBC fatty acid profiles of the partic-
ipants during the study. Red blood cell levels of EPA
were elevated (p < 0.0001) following both krill and fish
oil treatment compared with control treatment. On the
other hand, the RBC EPA level was higher (P = 0.0011)
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oil also elevated the RBC levels of DHA (p = 0.0011)
compared with control. However, no significant differ-
ences existed in the DHA levels after fish oil treatment
compared with control. Sum of EPA and DHA in RBC
membranes (as percent of total fatty acid content),
which is denoted as omega-3 index, increased following
krill (p < 0.0001) and fish oil consumption (p = 0.0043)
compared with control. Interestingly, krill oil treatment
elevated the omega-3 index compared with fish oil treat-
ment (p = 0.0143). The change in omega-3 index after
consumption of krill oil was two-fold higher than fish oil
(1.04% and 0.47% following krill and fish oil treatmentsTable 3 RBC composition of fatty acids and their changes wit
Parameter Treatment Baseline
Mean ± STD P. value1
EPA Krill oil 0.82 ± 0.23 0.8825
Fish oil 0.80 ± 0.23
Corn oil 0.80 ± 0.21
DPA Krill oil 2.24 ± 0.27 0.7470
Fish oil 2.29 ± 0.28
Corn oil 2.25 ± 0.34
DHA Krill oil 4.12 ± 0.83 0.2140
Fish oil 4.16 ± 0.73
Corn oil 4.21 ± 0.89
Total n-3 PUFA Krill oil 7.52 ± 1.03 0.4531
Fish oil 7.59 ± 0.86
Corn oil 7.59 ± 1.22
EPA + DHA Krill oil 4.94 ± 0.97 0.6873
Fish oil 4.96 ± 0.79
Corn oil 5.00 ± 1.02
n-6:n-3 ratio Krill oil 4.17 ± 0.68 0.4169
Fish oil 4.08 ± 0.47
Corn oil 4.14 ± 0.84
Total SFA Krill oil 43.55 ± 1.98 0.6065
Fish oil 43.58 ± 1.97
Corn oil 43.62 ± 2.44
Total MUFA Krill oil 18.21 ± 1.17 0.8825
Fish oil 18.17 ± 1.39
Corn oil 18.34 ± 1.49
Total PUFA Krill oil 38.25 ± 2.33 0.6065
Fish oil 38.25 ± 2.38
Corn oil 38.05 ± 2.73
Total n-6 PUFA Krill oil 30.73 ± 2.01 0.1969
Fish oil 30.66 ± 1.96
Corn oil 30.46 ± 2.13
Values are expressed as percentage of total fatty acids (n = 24). 1Friedman Test was
regarding the results in baseline, endpoint and change. * and # indicate significantrespectively; p = 0.0043). Similarly, krill oil treatment led
to an increase in RBC DPA levels compared with fish (p =
0.0412) and control oil (p = 0.0412) supplementation.
Treatment with fish oil failed to affect DPA levels in the
RBC. Both krill and fish oil treatments reduced (p =
0.0011) total n-6 fatty acid levels compared with control.
No differences in the n-6 PUFA concentrations were ob-
served with krill oil compared with fish oil intake. Similar
to plasma fatty acid results, no significant changes with
RBC total PUFA, MUFA and SFA concentrations were
seen between the three treatment phases. As expected,
krill and fish oil treatments increased RBC n-3 PUFA
levels (p < 0.0001 and p = 0.0143 for krill oil and fish oilh different interventions
End-Point Change
Mean ± STD P. value1 Mean ± STD P. value1
1.48 ± 0.38*# <0.0001 0.66 ± 0.29*# <0.0001
1.10 ± 0.25* 0.30 ± 0.26*
0.74 ± 0.22 −0.05 ± 0.16
2.42 ± 0.21*# 0.0421 0.18 ± 0.23 0.0787
2.28 ± 0.24 −0.01 ± 0.29
2.26 ± 0.27 0.00 ± 0.31
4.50 ± 0.75* 0.0039 0.38 ± 0.44*# 0.0002
4.34 ± 0.83 0.17 ± 0.64
4.12 ± 0.72 −0.09 ± 0.56
8.74 ± 1.08*# <0.0001 1.22 ± 0.77*# <0.0001
8.04 ± 1.00* 0.45 ± 1.00*
7.47 ± 0.95 −0.11 ± 0.90
5.97 ± 1.03*# <0.0001 1.04 ± 0.59*# <0.0001
5.43 ± 0.97* 0.47 ± 0.77*
4.86 ± 0.80 −0.14 ± 0.61
3.45 ± 0.59*# <0.0001 −0.72 ± 0.43*# <0.0001
3.77 ± 0.52* −0.31 ± 0.41*
4.20 ± 0.60 0.06 ± 0.56
43.12 ± 1.86 0.1969 −0.43 ± 1.86 0.0613
44.22 ± 2.05 0.64 ± 2.26
43.34 ± 1.51 −0.29 ± 1.92
18.55 ± 2.33 0.5134 0.34 ± 2.13 0.3114
17.82 ± 1.31 −0.35 ± 1.03
18.30 ± 1.32 −0.03 ± 0.93
38.33 ± 2.02 0.7470 0.08 ± 1.98 0.5818
37.96 ± 2.45 −0.29 ± 2.59
38.36 ± 2.03 0.32 ± 2.26
29.59 ± 2.01* 0.0107 −1.14 ± 1.66* 0.0003
29.92 ± 2.13* −0.74 ± 1.86*
30.89 ± 1.79 0.43 ± 1.65
used to test if there is a significant difference between treatment groups
difference compared with corn and fish oil treatments respectively.
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fish: p = 0.0143) compared with control. Krill oil treatment
also elevated the total n-3 PUFA concentrations (p =
0.0011) and reduced the n-6:n-3 ratio (p = 0.0143) com-
pared with the fish oil treatment. Total n-6 PUFA was
found to be reduced with both krill and fish oil phases
(p = 0.0143) compared to control. Furthermore, concen-
trations of n-6 PUFA were not significantly different
between krill and fish oil phases. Additionally, no signifi-
cant changes in total SFA, PUFA and MUFA concentra-
tions were observed between the three treatments in the
RBC (Additional file 1: Table S2).
Serum lipid concentrations of participants during the
study are portrayed in Table 4. Serum TG and HDL
cholesterol levels did not change across the three treat-
ments. However, total and LDL cholesterol concentra-
tions were found to be higher after krill oil (p = 0.0067;
p = 0.0143, for total and LDL cholesterol, respectively)
supplementation compared with control. Similarly, fish
oil consumption increased total and LDL cholesterol
levels (p = 0.0028; p = 0.0143, for total and LDL choles-
terol, respectively) compared with control oil supplemen-
tation. No differences were observed either in serum total
or LDL cholesterol concentrations or in the TC/HDL ratio
when comparing krill and fish oil consumption.
Overall, no differences were observed between base-
lines of either the fatty acid tested in each treatment or
the order of treatments or placebo received by the partici-
pants. In addition, no gender or age effect was found in
any of the parameters analyzed. Safety with consumptionTable 4 Serum lipid concentrations before and after each
treatment
Parameters Treatment Baseline Endpoint
(mg/dL) (mg/dL)
TG Krill oil 101.10 ± 10.53 99.86 ± 8.32
Fish oil 86.69 ± 6.73 89.20 ± 7.31
Corn oil 103.41 ± 9.84 103.45 ± 10.53
HDL Krill oil 55.74 ± 2.91 60.90 ± 2.91
Fish oil 56.71 ± 2.84 58.81 ± 2.76
Corn oil 56.22 ± 3.38 58.00 ± 3.07
LDL Krill oil 93.05 ± 4.66 101.31 ± 6.20*
Fish oil 94.78 ± 5.53 102.43 ± 5.81*
Corn oil 95.03 ± 4.82 93.25 ± 5.29
Total cholesterol Krill oil 168.85 ± 5.45 181.90 ± 6.75*
Fish oil 169.65 ± 5.60 179.22 ± 5.78*
Corn oil 172.55 ± 5.69 172.24 ± 5.99
Krill oil 3.21 ± 0.20 3.16 ± 0.22
Total cholesterol/HDL ratio Fish oil 3.21 ± 0.23 3.24 ± 0.21
Corn oil 3.29 ± 0.21 3.17 ± 0.21
Values are expressed as Mean ± SEM. n = 24. *denotes significance compared
with corn oil treatment.of krill and fish oil were determined by measuring blood
parameters including WBC, RBC, hematocrit, hemo-
globin, platelet count, neutrophils, lymphocytes, mono-
cytes, eosinophils, basophils, MCV, MCH and MCHC
values. No significant differences were found in any of the
above parameters with either krill or fish oil supplementa-
tion compared with control (Data not shown).
Medical history and physical examination revealed that
none of the participants had any health problems or
concerns which are known to affect study outcomes.
The study physician recorded and compared the health
status of participants at each visit. None of the partici-
pants during the study showed major changes in their
health status related to the trial.
No adverse or serious adverse events related to the
treatments were reported during the period of the study.
During the study one participant experienced a skin in-
fection, one had an allergic reaction and another partici-
pant had her appendix surgically removed. All these
three events occurred during the washout periods and
were deemed not related to the study. None of the par-
ticipants consumed any concomitant medications or
supplements that are known to affect study outcomes.
All participants reported followed guidelines not to eat
more than one serving per mo of fish or sea food. None of
the participants exceeded the limit of fish or sea food con-
sumption during intervention or washout periods. Partici-
pants consumed the study capsules regularly according to
the instructions. Participants were of high compliance
with capsule consumption which is evident from the cal-
culated self-reported compliance on capsule consumption.
The compliance ratings for capsule consumption during
krill and fish oil interventions were 95.79 ± 6.87% and
96.91 ± 5.86%, respectively. During the control oil inter-
vention, the compliance was 96.89 ± 4.27%.
Krill oil treatment failed to produce any gastrointes-
tinal symptoms compared with fish oil or placebo con-
trol interventions, except for burping and aftertaste
(Table 5). Four participants reported mild and three
moderate burping after krill oil consumption, whereas
only two participants reported burping (one mild and
one moderate) after consuming fish oil or placebo con-
trol intervention. Similarly, 7 participants reported hav-
ing aftertaste (six mild and one moderate) with krill oil
consumption. Three participants reported having a mild
aftertaste with fish oil consumption, however, none of
them felt any aftertaste with control oil consumption.
Two participants experienced mild hiccupping during
fish oil consumption but no hiccupping was reported
with krill oil or placebo control intervention.
Discussion
The current findings show, for the first time, that con-
sumption of 3 g/d krill oil for 4 wk increases the plasma
Table 5 Gastrointestinal responses from participants
GI symptoms Krill oil Fish oil Corn oil
(No. of participants) (No. of participants) (No. of participants)
Hiccup - Mild- 2 -
Burping Mild – 4 Mild – 1 Mild – 1
Moderate – 3 Moderate – 1 Moderate – 1
Nausea - - -
Vomiting - - -
Indigestion - Mild – 1 Mild – 1
Stomach/abdominal pain - Mild – 1 -
Constipation Mild – 1 - -
Diarrhea - - -
Flatulence Mild – 1 Mild – 2 Mild – 1
Abdominal bloating Mild – 2 Mild – 1 Mild – 1
Moderate – 1
Cramping - - -
Heartburn - - Mild – 1
After taste Mild – 6 Mild – 3 -
Moderate – 1
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the sum of EPA and DHA compared with fish and corn
oil in healthy humans. Krill oil consumption also re-
sulted in a significant decrease in the total n-6:n-3 PUFA
ratio and increased the omega-3 index compared with
fish oil and control treatments. Fish oil treatment also
significantly increased the plasma and RBC concentra-
tions of total n-3 PUFA and EPA and decreased the total
n-6:n-3 PUFA ratio compared with control. These re-
sults indicate that bioavailability of krill oil n-3 PUFA
might be more pronounced compared with that of fish
oil, likely due to the structural differences between these
two marine oils. Moreover, both krill and fish oil were
well tolerated by participants and caused no adverse ef-
fects which shows the safe nature of krill oil. According
to our knowledge, the current study is the first to com-
pare the effects of krill and fish oils on fatty acid profile
in plasma and RBC after 4 wk of consumption, using a
randomized crossover design.
In the present study, krill oil supplementation for 4 wk
resulted in a substantial increase in EPA total n-3 PUFA
and the sum of EPA and DHA levels in the plasma,
compared with fish oil treatment although fish oil also
increased the plasma EPA, DHA and total n-3 PUFA
compared with control. Since both krill and fish oil
treatments delivered the same amount of total n-3
PUFA, these findings indicate that the bioavailability of
n-3 PUFA from krill oil might be higher than that of n-3
PUFA from fish oil. Several studies were carried out
attempting to test the hypothesis that n-3 fatty acids will
be better absorbed as PL based oil, such as krill oil,compared with TG based oil, such as fish oil, [10,17] or
ethyl-esters [18]. However all of these trials, although
using different study designs, duration, selection criteria
and concentrations of the n-3 PUFA, consistently show
a non-significant increased bioavailability of n-3 PUFA
from krill oil compared with fish oil. It is very likely that
the reason for the poor results presented thus far is due
to use of study designs not suitable for absorption
studies.
Krill oil supplementation reduced plasma n-6 PUFA,
along with increases in n-3 PUFA concentrations, result-
ing in decreased n-6:n-3 PUFA ratio compared with fish
oil treatment. Furthermore, fish oil intake also reduced
the plasma n-6 PUFA and n-6:n-3 PUFA ratio compared
with control. In the current study, the lower plasma n-6
PUFA and n-6:n-3 PUFA ratio with krill oil intake com-
pared with fish oil intake might also be due to differ-
ences in fatty acid composition of the krill and fish oils
used. The n-6 PUFA content of the krill oil was low
(1.73 g/100 g oil) compared with fish oil (21.95 g/100 g
oil). The current study did not control the n-6 PUFA
concentrations between krill and fish oil. However, even
with higher n-6 PUFA content, fish oil treatment actu-
ally significantly reduced the plasma concentrations of
n-6 PUFA. Furthermore, n-6 PUFA consumption by the
participants was not controlled although n-3 PUFA con-
sumption was well controlled during the intervention
period. Amounts of n-6 PUFA in the diet might be
higher than the difference in the amount between the
different treatment oils. Hence, it is understandable that
consumption of both krill and fish oils resulted in
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decreased n-6:n-3 ratio along with elevations of total n-3
PUFA concentration.
Reduction in n-6:n-3 PUFA ratio after krill oil con-
sumption observed in the current study was in line with
previous reports analyzing the n-6:n-3 ratio with intake
of n-3 rich oils [10,17,19]. It has been shown that n-6:n-
3 PUFA ratio is strongly associated with CVD risk [20].
Hence, krill oil supplementation could be recommended
to increase the n-3 PUFA, omega-3 index and reduce
the n-6:n-3 PUFA ratio thereby reducing the risk of
CVD. Indeed, it is currently recommended that con-
sumption of 1-3 g/d of EPA and DHA through fish oil
reduces CVD risk [21,22]. However, evidence from epi-
demiological studies on effects of fish oil on CVD is in-
consistent with totally negative association [3,23] or no
effect [24,25] having been identified. Bioavailability of n-
3 PUFA could play a major role for these discrepancies.
It has been shown that DHA is highly absorbed when
delivered by PL compared with fish oil in mice deprived
of essential fatty acids [26]. Additional in vivo studies
using animal models demonstrated that the level of ab-
sorption of DHA into target tissues, such as brain and
heart, is affected by the source of the DHA. It was
shown that PL-bound DHA deliver the DHA to brains
hearts and liver in different animal models including
mice, rats and baboons more efficiently than TG-bound
DHA [14,26-28]. In humans, Carnielli et al. tested the
ability of preterm babies to absorb DHA given in formulas
enriched with DHA in PL form or TG forms [29]. The re-
sults showed that DHA in a PL form was absorbed signifi-
cantly better compared than in a TG form.
Sum of EPA and DHA in RBC has been considered as
the highly valuable omega-3 index and was demon-
strated to serve as a risk factor for death from CVD
[2,30,31]. In the current study, krill oil consumption re-
sulted in an elevated omega-3 index compared with
consumption of fish oil and control oil treatments, em-
phasizing the efficiency and higher bioavailability of krill
oil over fish oil. Concentrations of EPA and DHA in
RBC have a longer half-life of about 4–6 times compared
with plasma EPA and DHA [32], thus reflecting long term
intakes of n-3 PUFA status of individuals [2]. Measure-
ment of fatty acids in RBC reflects the tissue composition
and the concentrations of the EPA and DHA in RBC
which are not influenced by dyslipidemia [30]. Increased
n-3 PUFA concentrations in RBC have been shown to be
associated with reduced risk of CVD [2,33-35].
In the current study, both krill and fish oil treatments
failed to affect serum HDL and TG concentrations com-
pared with control. No significant differences were seen
with effects of krill oil compared with fish oil consumption
on serum lipid levels. Indeed, both krill and fish oils in-
creased serum total and LDL cholesterol concentrationscompared with control. Results are not surprising as the
participants used in the study were normolipidemic
healthy individuals. Studies have shown that higher dos-
ages of about 2–4 g/d of EPA and DHA were needed to
bring significant reductions in serum lipid concentrations
of normolipidemic participants [5,36,37]. Although krill
oil supplementation has demonstrated hypolipidemic ac-
tivity in some studies, this effect is found to be more pro-
nounced with participants with hyperlipidemia [11,36,38].
Similar results were found in previous studies with nor-
molipidemic participants in whom there was no effect on
serum lipids [10,17,39]. Reduction of serum TG by n-3
PUFA also depends on their baseline concentrations
[36,38,40]. Supplementation of 1–4 g/d of EPA reduced
serum TG in hyperlipidemic participants compared with
normolipidemics [41-44]. Consumption of n-3 PUFA from
fish oil increased the diameter of LDL particles [45] and
reduced the number of small dense LDL particles while
increasing LDL particle size which could be the reasons
for the increase in LDL in some studies [46,47].
In regards to safety parameters, krill oil supplementa-
tion of 4 wk was well tolerated, with participants experi-
encing no adverse events. No changes were seen in vital
signs, anthropometric measures and hematological vari-
ables or concerns by the study physician after the phys-
ical examination between the different treatments. Also,
treatment with krill oil did not change any of the gastro-
intestinal symptoms compared with fish oil or control
intervention except mild burping and aftertaste. The
findings on safety parameters along with the high com-
pliance from participants indicate the safety of krill oil
consumption as shown by other studies [10,17].
Strengths of the study
Selection of a randomized, placebo controlled, double
blinded crossover study design added robustness and in-
creased the statistical power of the present trial. Dosages
of n-3 PUFA for krill and fish oil treatments were kept
identical which enables the direct comparison between
the effects of krill and fish oil. Measurement of fatty
acids in RBC reflects the tissue composition and is not
influenced by dyslipidemic conditions. During the study,
all participants kept their dietary habits and physical activ-
ities constant. None of the participants consumed any
concomitant medications or supplementation or exceeded
more than one fish or sea food serving per month
throughout the study period which confirms that the
changes in the circulatory fatty acid profile of the partici-
pants were only from the intervention, without any other
dietary influence. Participants’ reported compliance with
each treatment was above 96% which adds strength to the
results and indicates the tolerability and acceptability of
the treatment capsules by the participants. The physical
examination of participants at baseline and endpoint by
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weekly telephone monitoring for compliance and adverse
events added strength to the study.
Limitations of the study
The n-6 fatty acid concentration in fish oil was higher
than krill oil which could influence the effects of n-3
fatty acids and the ratio between n-6 and n-3 fatty acids.
Although we found a significant beneficial effect in fatty
acid profile after krill oil consumption, the intervention
period of each treatment phase was only 4 weeks long.
In order to measure and achieve steady-state conditions
with circulatory n-3 PUFA concentration, longer inter-
vention periods could be recommended. Additionally,
testing and comparing effects of krill oil and fish oil con-
sumption over different time points would be very in-
formative. The current study was a free living design
which did not strictly control the macronutrient profile
of each participant diet. In addition, n-3 PUFA con-
sumption from sources other than marine foods was not
strictly controlled although participants were recom-
mended to keep their diets constant during the study. A
full feeding control study with all background diets and
n-3 PUFA well controlled could also be recommended.
In summary, the consumption of krill oil significantly
increased plasma and RBC concentrations of EPA along
with total n-3 PUFA levels; and decreased the n-6:n-3
PUFA ratio compared with fish oil and the control treat-
ments. The results indicate that there might be a higher
bioavailability of n-3 PUFA from krill oil over fish oil.
Krill oil also efficiently increased the omega-3 index
compared with fish oil and control. However, krill oil,
similar to fish oil, consumption resulted in a slight but
significant increase in total and LDL cholesterol without
altering the HDL and TG, in a manner that no alter-
ations were seen in the TC/HDL ratio. Overall, four wk
consumption of krill oil was well tolerated, and could be
more effective in increasing n-3 PUFA and omega-3
index than fish oil, with no indication of adverse effects.Figure 1 Schematic representation of the experimental protocol. B - 1
Inclusion and Exclusion criteria; PE - Physician examination; AE - Adverse ev
Left over capsules return; Q - Questionnaires (Fish and sea food consumptiParticipants and methods
Participant selection
Healthy males and premenopausal non pregnant or
nursing females (n = 24) ages 18–49 y were recruited by
advertisement at the Richardson Centre for Functional
Foods and Nutraceuticals on the University of Manitoba
campus. Participants were screened and excluded if they
reported any history of cancer, rheumatoid arthritis,
chronic illness, cardiovascular problems, hepatobiliary
and renal disease, diabetes mellitus, inflammatory bowel
disease, pancreatitis, neurological/psychological disease,
bleeding disorders, experienced platelet abnormalities,
and gastrointestinal disorders that could interfere with
fat absorption. In addition, participants were excluded if
they admitted an allergy to fish or sea foods, or reported
consuming supplements including n-3 PUFA in the past
6 mo or consuming more than one fish serving per mo
during the mo prior to the start of the study. Partici-
pants were included if they were nonsmokers, with
serum TG levels less than 200 mg/dL, total cholesterol
less than 240 mg/dL, LDL-cholesterol less than 160 mg/
dL, BMI less than 28, not consuming more than one al-
coholic drink/d and not taking any medications that
would interfere with lipid metabolism or to control
blood lipids or treat hypertension. The protocol of the
study with all procedures was reviewed and approved by
the Human Ethical Review Committee of the University
of Manitoba (B2011: 014). All participants were ex-
plained the study protocol and written consent was
obtained.
Study design and intervention
The study design was a randomized, placebo controlled,
double blinded, crossover, conducted to comply with
Good Clinical Practice guidelines and in accordance with
the Helsinki declaration of 1975 as revised in 1983. The
study included three treatment periods. Each treatment
phase lasted 4 wk and was separated by washout phases
of 8 wk (Figure 1). Washout period of 8 wk was chosen2 h fasted blood collection; AN - Anthropometric measurements; IE -
ents; CD - Capsule dispensation (KO or FO or corn oil capsules); CR -
on, concomitant medications); GI - Gastro intestinal questionnaires.
Table 6 Fatty acid composition of krill, fish and corn oil
used in the study
Fatty acid (% of total fatty acids) Krill oil Fish oil Corn oil
C12 (Lauric) 0.27 0.16 0.13
C14 (Myristic) 11.82 4.49 0.00
C14:1 (Myristoleic) 0.16 0.12 0.00
C15 (Pentadecanoatenoic) 0.47 0.35 0.00
C16 (Palmitic) 22.11 17.06 15.01
C16:1 (Palmitoleic) 6.09 6.53 0.00
C17 (Margaric) 2.02 0.38 0.00
C18 (Stearic) 1.39 3.54 3.31
C18:1n9 (Oleic) 13.28 2.62 1.08
C18:1n7 (Vaccenic) 7.56 0.00 0.00
C18:2n6 (Linoleic) 2.06 32.49 77.57
C18:3n6 (gamma-Linolenic) 0.00 0.24 0.00
C18:3n3 (alpha-Linolenic) 0.93 1.28 1.61
C18:4n3 (Moroctic) 2.70 2.67 0.00
C20 (Arachidic) 0.00 0.50 0.57
C20:1n9 (Eicosenoic) 0.80 1.04 0.44
C20:2n6 (Eicosadienoic) 0.41 0.00 0.00
C20:4n6 (Arachidonic) 0.40 0.65 0.00
C20:4n3 (Eicosatetraenoic) 0.26 0.80 0.00
C20:5n3 (Eicosapentaenoic) 16.44 13.46 0.00
C22 (Behenic) 0.00 0.73 0.27
C22:1n9 (Euricic) 0.56 0.00 0.00
C22:2n9 (Docosadienoic) 0.43 0.50 0.00
C22:5n3 (Docosapentaenoic) 0.38 1.36 0.00
C22:6n3 (Docosahexaenoic) 9.48 8.66 0.00
C24:1n9 (Nervonic) 0.00 0.35 0.00
Total n-3 PUFA 30.18 28.24 1.61
Total n-6 PUFA 2.86 33.38 77.57
Total n-9 PUFA 15.07 4.51 1.52
Total PUFA 33.47 62.11 79.18
Total MUFA 28.46 10.67 1.52
Total SFA 38.07 27.22 19.30
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acid supplementation [48]. Stratified randomization was
used to allocate participants to the 3 possible treatment
sequences so that an equal number of men and women
were allocated to each sequence. Interventions were
conducted during May and December 2011. Participants
were provided with identical looking capsules containing
krill, fish or corn oil on the first d of each treatment
phase. During each treatment period, participants con-
sumed 6 capsules per d, 3 in the morning and 3 at night
along with their meals and each capsule consisting of
500 mg of one of the oils (a total of 3 g which were
taken in six 500 mg capsules, krill oil (K•REAL™) was
supplied by Enzymotec Ltd. and fish oil was Omevital
TG 18/12 supplied by Napro Pharma, Norway). Fatty
acid composition of krill, fish and corn oils are shown in
Table 6. Daily doses of both krill and fish oil treatments
provided 600 mg of n-3 PUFA. However, only krill oil
capsules delivered 1800 μg/d of astaxanthin in addition
to the fatty acids.
Body weight, blood pressure, waist and hip circumfer-
ence measurements and physical examinations were per-
formed at baseline and endpoint of each treatment
following standard procedures [49]. Gastrointestinal tol-
erability and well-being questionnaires were assessed at
the endpoint of each treatment. Blood samples after
12 h fasting were collected at baseline and endpoint of
each phase. Samples were centrifuged at 3000 rpm for
20 min followed by separation of plasma and RBC and
aliquots were stored in −80 degrees C until analysis.
A weekly telephone questionnaire was completed by
study coordinators to monitor treatment adherence and
safety during the study period. Questions included; cap-
sule intake, fish or sea food intake, adverse events and
concomitant medication use. In addition, participants
recorded their capsule consumption and remaining
capsules were returned at the end of each phase. Com-
pliance was calculated using the number of remaining
capsules returned and written records kept by the
participants.
Plasma and RBC fatty acid analyses
Plasma and RBC total lipids were extracted using the
Folch method [50] which involved chloroform-methanol
(2:1, v/v) containing 0 · 01% BHT (Sigma-Aldrich, Oakville,
ON, Canada) and heptadecanoic acid as an internal stand-
ard (Sigma-Aldrich, Oakville, ON, Canada). Extracted
fatty acids were methylated with methanolic HCl. Fatty
acid methyl esters were separated on a Supelcowax 10 col-
umn (30 m X 0 · 25 mm with 0 · 25 mm film thickness;
Supelco, Bellefonte, PA, USA) using a gas chromatograph
equipped with a flame ionisation detector (Bruker 430).
The oven was programmed from 70 to 240 degrees C with
the following temperature steps (70 degrees C for 2 min,rise of 30 degrees C/min, 180 degrees C for 1 min, rise of
10 degrees/min, 200 degrees C for 2 min, rise of 2 degrees
C/min, 220 degrees C for 4 min, rise of 20 degrees/min,
240 degrees for 6 min). Samples were analyzed with a 20:1
split ratio; helium was used as the carrier gas with a col-
umn flow rate of 1.0 ml/min. Temperatures of the injector
and detector were set at 270 and 290 degrees C, respect-
ively. Individual fatty acids were identified by comparison
with known standards (NuChek Prep, Inc., Elysian, MN,
USA). Individual fatty acids were calculated according to
the peak area relative to the total area and expressed as
the percentage of total fatty acids.
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Serum lipid profile including total and HDL-cholesterol
and TG levels were measured using a Vitros 350 Autoana-
lyser (Orthoclinical diagnostics). LDL-cholesterol levels
were calculated using Friedewald equation [51]. Complete
blood counts were also determined using a Beckmann
coulter LH780 at baseline and at endpoint of each treat-
ment phase.
Statistical analysis
Differences between krill oil, fish oil, and placebo control
interventions were analyzed for each dependent meas-
ure. Friedman Test was used to test for significant differ-
ences between treatment groups regarding the results in
baseline, end-point and change between baseline and
end-point. Data were analyzed using SAS statistical soft-
ware, version 9.2. Values were expressed as mean ± STD
and p values <0.05 were considered significant. Safety
data were examined descriptively for each arm and com-
pared across treatments. Furthermore, statistical analyses
such as Kruskal-Wallis and Friedman tests were used to
identify significant differences between different phases
regarding baseline result for each treatment separately
and if significant differences existed between phases re-
garding the baseline measures (ignoring the treatment
effect). These tests were done to determine the efficiency
of the washout period.
Additional file
Additional file 1: Table S1. Plasma secondary fatty acids composition
in individuals after interventions. Table S2: RBC secondary fatty acids
composition in individuals after interventions.
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